Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon liraglutide Prior Auth→Step Coverage | …
    Ask Trek AI about this page
    CurrentcareoregonPolicy N/A

    Prior authorization guideline — Liraglutide (generic)

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization guideline for liraglutide (generic) covering multiple indications including type 2 diabetes, chronic kidney disease, and diabetes with obstructive sleep apnea for CareOregon Medicaid members.

    Policy Summary
    Payercareoregon
    PolicyPrior authorization guideline — Liraglutide (generic)
    Policy CodePolicy N/A
    Change TypeGuideline type changed to Step therapy
    Effective DateJul 22, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document required prior trials or contraindications per step therapy before approval.
    SourceLink
    POLICY UPDATE CHANGES

    Changed guideline type from PA to Step.

    3indication criteria sets
    2717005000D220covered GPI
    >30BMI threshold
    25-75eGFR range

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Type 2 Diabetes with Obstructive Sleep Apnea

    Covered when ALL of the following are met:

    Type 2 Diabetes with OSA: 1) Diagnosis of Type 2 Diabetes; 2) One of the following: 2.1 Trial of and will continue therapy with metformin OR 2.2 Failure, contraindication, or intolerance to metformin; 3) Patient has a BMI greater than 30 kg/m2; 4) Diagnosis of moderate to severe obstructive sleep apnea confirmed by polysomnography; 5) One of the following: 5.1 Patient has fully maximized the use of positive airway pressure therapy OR 5.2 Submission of medical records documenting an inability to tolerate positive airway pressure therapy; 6) Patient has tried a weight loss treatment plan administered by a health care provider for at least a 3-month period within the past 6 months.

    From chunks 7 and 3.

    Type 2 Diabetes - general criteria

    Covered when ALL of the following are met:

    Diabetes - general: One of the following: trial and failure of an SGLT2 inhibitor or a DPP-4 inhibitor OR both: patient has ASCVD and failure, contraindication, or intolerance to an SGLT2 inhibitor.

    From chunks 3 and 4.

    Chronic Kidney Disease

    Covered when ALL of the following are met:

    CKD: 1) Diagnosis of chronic kidney disease (stage 2-4); 2) Submission of medical records (e.g., chart notes) documenting one of the following: stage 2-4 CKD OR eGFR of 25-75 mL/min/1.73m2 OR urine albumin-to-creatinine ratio (uACR) > 30 mg/g; 3) Failure, contraindication, or intolerance to an SGLT2 inhibitor.

    From chunks 5 and 6.

    No explicit exclusions are listed in this prior authorization guideline.

    The policy does not specify items described as "not medically necessary."

    Coding and Clinical Thresholds

    Covered GPImixedCovered
    2717005000D220LIRAGLUTIDE SOLN PEN-INJECTOR 18 MG/3ML (6 MG/ML) - Generic (GPI)
    inv-07: eGFR — 25-75 mL/min/1.73m2
    eGFR range25-75 mL/min/1.73m2
    ContextUsed as documentation of CKD staging for coverage for chronic kidney disease indication
    Source guidanceSubmission of medical records documenting eGFR of 25-75 mL/min/1.73m2 is accepted evidence
    inv-08: uACR — > 30 mg/g
    uACR threshold> 30 mg/g
    ContextUrine albumin-to-creatinine ratio used as alternative documentation of CKD staging for coverage
    Source guidanceSubmission of medical records documenting uACR greater than 30 mg/g is accepted evidence
    inv-09: BMI — > 30 kg/m2
    BMI threshold> 30 kg/m2
    ContextRequired criterion for the Type 2 Diabetes with Obstructive Sleep Apnea indication
    Source guidancePatient must have a BMI greater than 30 kg/m2 to meet this criterion

    Provider Actions & Authorization Rules

    Prior Authorization

    Prior authorization (step therapy) required for generic liraglutide

    Prior authorization (step therapy) is required for the generic liraglutide product (GPI 2717005000D220) and indication-specific criteria must be met before approval.

    Step Therapy

    Step therapy — required prior trials or documented contraindications

    Step therapy requires documented trials and failures of specified alternatives or a documented contraindication/intolerance prior to approval.

    • For general type 2 diabetes: trial and failure of an SGLT2 inhibitor or a DPP-4 inhibitor (or if ASCVD present, failure/contraindication/intolerance to an SGLT2 inhibitor).
    • For type 2 diabetes with OSA: trial of and continuation of metformin, or documented failure/contraindication/intolerance to metformin.
    • For chronic kidney disease: failure, contraindication, or intolerance to an SGLT2 inhibitor is required.
    Documentation Required

    Required supporting documentation (medical records/chart notes)

    Submit medical records or chart notes that demonstrate the clinical thresholds and required evaluations relevant to the requested indication.

    • For CKD: documentation of stage 2–4 CKD, or eGFR 25–75 mL/min/1.73m2, or uACR > 30 mg/g.
    • For diabetes with OSA: polysomnography confirmation of moderate–severe OSA and records showing either maximized positive airway pressure therapy or inability to tolerate such therapy.
    • For diabetes with OSA: documentation of BMI > 30 kg/m2 and a weight-loss treatment plan ≥3 months within the past 6 months.
    Denial Risk

    Denial triggers — missing prior trials or clinical documentation

    Requests may be denied if required prior therapy trials, contraindications/intolerance, or clinical documentation for the selected indication are not provided.

    • Missing documentation of trial and failure of an SGLT2 or DPP-4 inhibitor when required (or SGLT2 failure/contraindication when ASCVD present).
    • For diabetes with OSA, absence of a metformin trial or documentation of metformin contraindication/intolerance when applicable.
    • Insufficient evidence of CKD staging, eGFR/uACR values, OSA confirmation, BMI > 30 kg/m2, or failure/intolerance statements for positive airway pressure therapy.

    Initial Therapy Requirements

    Initial therapy requirements

    Initial authorization requires demonstration of prior therapy trials or documented contraindications/intolerance as specified below:

    Initial step: Trial and failure of an SGLT2 inhibitor or a DPP-4 inhibitor OR if patient has ASCVD, failure/contraindication/intolerance to an SGLT2 inhibitor; for Type 2 Diabetes with OSA indication, trial of and continuation of metformin or documented metformin contraindication/intolerance is required.

    From chunks 3, 4, and 7.

    Step Therapy

    StepRequirementProvider action
    1
    Step therapy applies: prior trial and documented failure OR documented contraindication/intolerance to the specified alternative therapies before approval (e.g., for general Type 2 diabetes: trial and failure of an SGLT2 inhibitor or a DPP-4 inhibitor; for Type 2 diabetes with OSA: trial of and continuation of metformin or documented failure/contraindication/intolerance to metformin).
    Document the prior trial(s) and outcome(s) or a documented contraindication/intolerance in the medical record and submit chart notes with the prior authorization request; lack of this documentation may result in denial.

    Definitions and Documentation

    inv-15: CKD documentation — Chronic kidney disease staging evidence
    Acceptable evidence of CKD stagingStage 2-4 chronic kidney disease (documented in medical records)
    eGFREstimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m2 (documented)
    uACRUrine albumin-to-creatinine ratio (uACR) greater than 30 mg/g (documented)
    Additional requirementFailure, contraindication, or intolerance to an SGLT2 inhibitor is required for CKD indication
    inv-16: OSA documentation — Obstructive sleep apnea requirements
    OSA diagnostic confirmationDiagnosis of moderate to severe obstructive sleep apnea confirmed by polysomnography
    Positive airway pressure therapyPatient has fully maximized use of positive airway pressure therapy
    Intolerance documentationOr submission of medical records documenting an inability to tolerate positive airway pressure therapy
    Associated requirementsAlso requires BMI > 30 kg/m2 and trial of/continuation of metformin or metformin intolerance for the diabetes with OSA indication

    Background

    Liraglutide is a GLP-1 receptor agonist used for glycemic control in type 2 diabetes and has evidence for weight reduction. This guideline applies step therapy expectations and requires indication-specific clinical documentation (for example, prior trials of specified alternatives for diabetes and measurable thresholds for comorbid conditions) before authorization is approved.

    Revision History

    as writtenoperational changeLatest

    Changed guideline type from PA to Step (operational change to step therapy requirement).

    Policy Summary
    Payercareoregon
    PolicyPrior authorization guideline — Liraglutide (generic)
    Policy CodePolicy N/A
    Change TypeGuideline type changed to Step therapy
    Effective DateJul 22, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document required prior trials or contraindications per step therapy before approval.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Actions & Authorization RulesInitial Therapy RequirementsStep TherapyDefinitions and DocumentationBackgroundRevision History